BioMarin Pharmaceutical, Inc. (BMRN)
56.03
-0.09
(-0.16%)
USD |
NASDAQ |
Nov 06, 16:00
56.00
-0.02
(-0.04%)
After-Hours: 20:00
BioMarin Pharmaceutical Cash from Investing (Quarterly) : -306.90M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -306.90M |
| June 30, 2026 | -5.102B |
| March 31, 2026 | 725.53M |
| December 31, 2025 | -42.45M |
| September 30, 2025 | -330.96M |
| June 30, 2025 | -12.59M |
| March 31, 2025 | -28.24M |
| December 31, 2024 | 76.40M |
| September 30, 2024 | -16.16M |
| June 30, 2024 | 90.48M |
| March 31, 2024 | -14.24M |
| December 31, 2023 | -64.96M |
| September 30, 2023 | -45.80M |
| June 30, 2023 | 29.53M |
| March 31, 2023 | -30.01M |
| December 31, 2022 | -54.71M |
| September 30, 2022 | -23.40M |
| June 30, 2022 | -29.70M |
| March 31, 2022 | 87.78M |
| December 31, 2021 | -55.42M |
| September 30, 2021 | -119.85M |
| June 30, 2021 | -120.26M |
| March 31, 2021 | -70.79M |
| December 31, 2020 | 11.03M |
| September 30, 2020 | 106.70M |
| Date | Value |
|---|---|
| June 30, 2020 | -248.75M |
| March 31, 2020 | 77.40M |
| December 31, 2019 | -48.90M |
| September 30, 2019 | 48.68M |
| June 30, 2019 | 19.67M |
| March 31, 2019 | -50.48M |
| December 31, 2018 | -70.96M |
| September 30, 2018 | 402.33M |
| June 30, 2018 | 4.722M |
| March 31, 2018 | -71.73M |
| December 31, 2017 | 139.55M |
| September 30, 2017 | -430.23M |
| June 30, 2017 | -39.82M |
| March 31, 2017 | 25.05M |
| December 31, 2016 | -309.65M |
| September 30, 2016 | -326.94M |
| June 30, 2016 | 75.54M |
| March 31, 2016 | 77.00M |
| December 31, 2015 | 79.55M |
| September 30, 2015 | -63.08M |
| June 30, 2015 | -445.20M |
| March 31, 2015 | -750.87M |
| December 31, 2014 | 461.24M |
| September 30, 2014 | -187.23M |
| June 30, 2014 | -40.37M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Exelixis, Inc. | -6.708M |
| Ascendis Pharma A/S | -3.268M |
| Alnylam Pharmaceuticals, Inc. | -311.74M |
| Anika Therapeutics, Inc. | -1.28M |
| Cytokinetics, Inc. | 67.93M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 188.21M |
| Cash from Financing (Quarterly) | -18.83M |
| Free Cash Flow | 555.50M |
| Free Cash Flow Per Share (Quarterly) | 0.8541 |
| Free Cash Flow to Equity (Quarterly) | 177.08M |
| Free Cash Flow to Firm (Quarterly) | 217.21M |
| Free Cash Flow Yield | 5.10% |